BOSTON – An owner and four former employees of New England
Compounding Center (NECC) were convicted today by a federal jury for their
roles at NECC, the company that caused the 2012 nationwide fungal meningitis
outbreak. The outbreak was the largest public health crisis ever caused by a
pharmaceutical drug. With today’s convictions, 11 former owners, executives,
and employees of NECC have been convicted of federal criminal charges.
“These defendants were professionals who acted recklessly to
the extreme detriment of public health,” said United States Attorney Andrew
Lelling. “Over the course of years, the defendants callously disregarded
patient health by cutting corners and prioritizing profits over safety. And
they got away with it by defrauding federal and state regulators. The result
was contaminated, deficient, deadly drugs that never should have been made or
distributed. Ultimately, the jury found the defendants’ fraudulent conduct
wrong and deserving of punishment. I applaud the prosecutors and the
investigative team on their dogged determination to bring us another step
closer to justice for the victims and their families.”
“A key aspect of the FDA’s mission is to ensure that drugs
are made under high quality conditions to prevent patient harm due to poorly
compounded products,” said FDA Commissioner Scott Gottlieb, M.D. “This episode
was a tragic reminder of why compounding and compounded drugs can present
serious risks to patients. We’ve taken significant new steps to ensure the
quality of compounded drugs and improve patient safety, in order to prevent
another calamity like the episode involving NECC. However, we continue to see
significant risk associated with some compounded drugs, and firms that produce
and ship drugs in bulk without any regard for product quality and patient
safety. We’re increasing our oversight in this space to crack down on activity
that puts patients at risk. At the same time, we’re continuing to advance new
policies to help responsible firms that are seeking to stay in compliance with
quality standards find efficient ways to meet those requirements.”
“These defendants callously ignored their professional
responsibilities to protect patient safety,” said Harold H. Shaw, Special Agent
in Charge of the FBI Boston Division. “Their failure to safeguard the public
played a significant role in the distribution of medicines that were harmful.
The FBI will continue to work with our law enforcement partners to combat fraud
and abuse in the health care system, so that we can do everything we possibly
can to protect the American public from harm.”
Following an 8-week trial, the following defendants were
found guilty by a federal jury:
Gene Svirskiy, 37, of Ashland, Mass., a former NECC clean
room pharmacist, who supervised NECC’s production of high-risk heart
medications, was convicted of racketeering, racketeering conspiracy, 10 counts
of mail fraud, and two counts of introduction of adulterated drugs into interstate
commerce with intent to defraud or mislead. Judge Richard G. Stearns scheduled
Svirskiy’s sentencing for March 11, 2018. Svirskiy faces a sentence of no
greater than 20 years in prison.
Christopher Leary, 34, of Shrewsbury, Mass., an NECC clean
room pharmacist, was convicted of three counts of mail fraud, one count of
introduction of adulterated drugs into interstate commerce with intent to
defraud or mislead, and two counts of introduction of misbranded drugs into
interstate commerce. Leary’s sentencing is scheduled for March 14, 2018. Leary
faces a sentence of no greater than 20 years in prison.
Sharon Carter, 54, of Hopkinton, Mass., NECC’s former
director of operations, was convicted of conspiracy to defraud the United
States. Carter’s sentencing is scheduled
for March 21, 2018. She faces a sentence of no greater than five years in
prison.
Alla Stepanets, 38, of Framingham, Mass., one of NECC’s
verification pharmacists, was convicted of six counts of introduction of
misbranded drugs into interstate commerce. Sentencing is scheduled for March
26, 2018. She faces a sentence of no greater than one year in prison.
Greg Conigliaro, 53, of Southborough, Mass., a former owner
of NECC, was convicted of conspiracy to defraud the United States. Judge
Stearns scheduled Conigliaro’s sentencing for March 28, 2018. He faces a
sentence of no greater than five years in prison.
Sentences are imposed by a federal district court judge
based upon the U.S. Sentencing Guidelines and other statutory factors.
Joseph Evanosky, 46, of Westford, Mass., a former clean room
pharmacist, was acquitted.
In 2012, 753 patients in 20 states were diagnosed with a
fungal infection after receiving injections of preservative-free
methylprednisolone acetate (MPA) manufactured by NECC. Of those 753 patients,
the U.S. Centers for Disease Control and Prevention (CDC) reported that 64
patients in nine states died. The government has since identified a total of
793 patients throughout the country harmed by NECC’s contaminated MPA. More
than 100 patients have now died.
The criminal investigation revealed that in addition to the
contaminated MPA, NECC’s other pharmacists, including Svirskiy and Leary,
knowingly made and sold numerous drugs in a similar unsafe manner and in
insanitary conditions. The unsafe manner included, among other things, the
pharmacists’ failure to properly sterilize NECC’s drugs, failure to properly
test NECC’s drugs for sterility, and failure to wait for test results before
sending the drugs to customers. They also approved the use of expired drug
ingredients, and the mislabeling of those drugs in order to deceive customers.
The insanitary conditions included, among other things, NECC’s lack of proper
cleaning and NECC’s failure to take any action when its own environmental
monitoring repeatedly detected mold and bacteria within NECC’s clean rooms
throughout 2012.
NECC repeatedly took steps to shield its operations from
regulatory oversight by the FDA by claiming to be a pharmacy dispensing drugs
pursuant to valid, patient-specific prescriptions. In fact, NECC routinely
dispensed drugs in bulk without valid prescriptions. Despite this practice,
Conigliaro, an owner of NECC, repeatedly misrepresented to the FDA and the
Massachusetts Board of Pharmacy that NECC was only dispensing drugs pursuant to
patient-specific prescriptions. Carter, NECC’s director of operations, directed
employees to engage in a number of fraudulent prescription schemes to deceive
regulators by creating the appearance that NECC had prescriptions for the drugs
it was selling. To that end, defendant Stepanets, one of NECC’s verification
pharmacists, was convicted of approving shipments of drugs for patients with
names such as Wonder Woman, Fat Albert, Bud Weiser, Samuel Adams, Hindsight
Man, Betty Ford, Jimmy Carter, Bill Clinton, Donald Trump, Calvin Klein and
Jennifer Lopez.
“Today’s verdicts demonstrate the ongoing commitment of the
Defense Criminal Investigative Service (DCIS) to ensure the integrity of
TRICARE, the U.S. Defense Department’s health care program,” stated Special
Agent-in-Charge Leigh-Alistair Barzey, DCIS Northeast Field Office. “DCIS will
continue to work with its law enforcement partners and the U.S. Attorney's
Office to identify individuals and companies who disregard laws and regulations
involving pharmaceuticals and, in so doing, endanger the health and safety of
U.S. military members and their families.”
“It is appalling that NECC staff engaged in this blatant
fraudulent activity with such reckless disregard for patient safety,” said Sean
Smith, Special Agent in Charge of the Department of Veterans Affairs Office of
Inspector General, Criminal Investigations Division. “This verdict should send
a clear message to individuals and businesses that VA OIG and its law
enforcement partners will vigorously investigate healthcare fraud that puts the
public and veterans at risk.”
“Today’s verdicts demonstrate the commitment of the U.S
Postal Inspection Service to bring justice to those who put our customers, the
American public, at risk,” said U.S. Postal Inspection Service’s Inspector in
Charge, Joseph W. Cronin of the Boston Division. “The cooperation and hard work
of our fellow law enforcement agencies and the Department of Justice
illustrates the common mission of protecting our citizens.”
In June 2017, Barry Cadden, the former owner and head
pharmacist for NECC, was sentenced to nine years in prison and three years of
supervised release after being convicted of racketeering, racketeering
conspiracy, mail fraud and introduction of misbranded drugs into interstate
commerce with the intent to defraud and mislead. In January 2018, Glenn Chin,
NECC’s former supervisory pharmacist, was sentenced to eight years in prison
and two years of supervised release after being convicted of 77 counts.
Two remaining defendants, Kathy Chin, and Michelle Thomas,
of Cumberland, R.I., both of whom were former verification pharmacists, are
scheduled to stand trial on March 25, 2019.
U.S. Attorney Lelling, FDA Commissioner Gottlieb, M.D., FBI
SAC Shaw, DCIS SAC Barzey, VA OIG SAC Smith, and Inspector Cronin made the
announcement today. Assistant U.S.
Attorneys George P. Varghese and Amanda P.M. Strachan of Lelling’s Criminal
Division prosecuted the case.
No comments:
Post a Comment